Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib

PURPOSE: Pancreatic cancer (PCa) is projected to become the second leading cause of cancer-related deaths by 2030. Gemcitabine (GEM) combined with erlotinib (ERL) have been approved by the FDA for locally advanced, unresectable or metastatic pancreatic cancer therapy since 2005. Type-1 matrix metall...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Na, Yu, Hui, Zhang, Xiaodi, Lv, Xiaodan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591159/
https://www.ncbi.nlm.nih.gov/pubmed/33122890
http://dx.doi.org/10.2147/DDDT.S270303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591159/
https://www.ncbi.nlm.nih.gov/pubmed/33122890
http://dx.doi.org/10.2147/DDDT.S270303

Ejemplares similares